believ
today
nucleocapsid
protein
n
sever
acut
respiratori
syndrom
sar
cov
one
promis
antigen
candid
vaccin
design
studi
three
fragment
residu
residu
residu
n
protein
sarscov
express
escherichia
coli
analyz
pool
sera
convalesc
phase
sar
patient
three
gene
fragment
nt
nt
nt
express
protein
respect
sarsn
clone
use
immun
balbc
mice
electropor
humor
enzymelink
immunosorb
assay
elisa
cellular
cell
prolifer
assay
immun
detect
use
recombin
specif
antigen
result
show
fragment
n
protein
express
e
coli
abl
react
sera
sar
patient
could
specif
humor
cellular
immun
mice
could
induc
significantli
inocul
sarscov
dna
vaccin
addit
immun
respons
level
significantli
higher
antibodi
respons
igg
cell
prolifer
assay
compar
vaccin
identif
antigen
n
protein
fragment
implic
provid
basic
inform
design
dna
vaccin
sarscov
present
result
suggest
dna
immun
could
use
potenti
dna
vaccin
approach
induc
antibodi
balbc
mice
also
illustr
gene
immun
sar
dna
vaccin
gener
differ
immun
respons
lifethreaten
highli
emerg
diseas
call
sever
acut
respiratori
syndrom
sar
origin
china
late
spread
rapidli
mani
countri
upon
outbreak
worldwid
collabor
network
coordin
result
extraordinari
endeavor
march
sarscov
novel
type
coronaviru
identifi
etiolog
agent
sar
genom
sequenc
sarscov
complet
found
sarscov
featur
characterist
coronavirus
group
iiii
quit
uniqu
correspond
author
tel
fax
repres
new
group
group
iv
sarscov
believ
mutant
coronaviru
transmit
wild
anim
develop
abil
product
infect
human
till
date
oper
treatment
sar
quarantin
transmissionblock
measur
mean
exist
curb
ruinou
impact
individu
convalesc
sar
seen
develop
high
titr
neutral
antibodi
moreov
appear
antibodi
coincid
onset
sar
pneumonia
report
point
possibl
vaccin
effect
therapi
sarscov
prevent
vaccin
would
promis
option
less
reliant
individu
case
detect
effect
even
though
vaccin
current
licens
see
front
matter
elsevi
bv
right
reserv
human
cov
vaccin
success
produc
anim
cov
certain
strain
infecti
bronchiti
viru
poultri
bovin
coronaviru
canin
coronaviru
genom
sarscov
singlestrand
plussens
rna
kb
length
contain
five
major
open
read
frame
orf
encod
nonstructur
replicas
polyprotein
structur
protein
spike
envelop
e
membran
nucleocapsid
protein
n
order
approxim
size
coronavirus
sarscov
nucleocapsid
n
gene
encod
protein
harbour
put
nuclear
local
signal
howev
n
protein
distribut
predominantli
cytoplasm
sarscovinfect
n
genetransfect
cell
sarscov
n
protein
highli
charg
basic
protein
selfassoci
form
dimmer
threedimension
structur
ntermin
portion
protein
share
similar
rnabind
protein
coronaviru
n
protein
thought
particip
replic
transcript
viral
rna
interfer
cellcycl
process
host
cell
result
play
critic
role
sar
cov
pathogenesi
addit
n
protein
mani
coronavirus
highli
immunogen
express
abundantli
infect
high
level
igg
antibodi
n
detect
sera
sar
patient
n
protein
induc
protect
immun
least
set
protect
respons
coronavirus
report
n
protein
repres
antigen
tcell
respons
vaccin
set
induc
sarsspecif
tcell
prolifer
cytotox
tcell
activ
induc
virusspecif
cellular
respons
human
cell
use
mous
model
observ
hypothes
n
protein
express
viral
infect
cell
may
effect
mediat
potenti
target
sarscov
vaccin
address
issu
therefor
focus
studi
character
n
protein
residu
aa
fulllength
sequenc
protein
residu
aa
ntermin
region
residu
aa
middl
plu
c
termin
region
sarscov
target
antigen
vaccin
develop
construct
eukaryot
express
plasmid
encod
n
nucleotid
nucleotid
nucleotid
gene
fragment
sarscov
compar
individu
potenti
immun
respons
balbc
mice
use
develop
sar
vaccin
candid
therefor
safe
effect
sar
vaccin
would
highli
benefici
human
health
system
dna
fragment
contain
full
length
truncat
sarscov
n
gene
gener
pcr
use
sarscov
strain
hanoi
cdna
templat
tabl
show
forward
revers
primer
pcr
cycl
condit
use
order
subclon
pcr
product
bam
fragment
vector
novagen
germani
plasmid
contain
n
gene
transform
escherichia
coli
strain
origami
tm
b
sarscov
n
protein
express
induc
transform
compet
cell
ad
mm
iptg
invitrogen
usa
h
express
n
protein
contain
small
hexahistidin
tag
c
terminu
subsequ
purifi
use
bind
purif
kit
novagen
niida
resin
column
confirm
sdspage
use
polyacrylamid
gel
follow
western
blot
use
mous
antisar
n
protein
monoclon
antibodi
dilut
zyme
usa
horseradish
peroxidas
hrp
conjug
goat
antimous
igg
dilut
zyme
usa
primari
secondari
antibodi
respect
purifi
protein
analyz
pool
sera
convalesc
phase
sar
patient
posit
control
healthi
volunt
neg
control
present
studi
use
invitrogen
usa
contain
cmv
promot
bgh
polyadenyl
sequenc
highlevel
mammalian
express
dna
vaccin
gener
dna
fragment
encod
sarscov
nucleocapsid
amplifi
pcr
use
set
primer
templat
tabl
amplifi
product
clone
pgem
easi
vector
promega
uk
pgemtn
gene
digest
bam
hi
psti
roch
switzerland
insert
vector
accuraci
construct
confirm
dna
sequenc
genotech
compani
seoul
korea
sequenc
ident
report
sequenc
gene
bank
access
number
gi
dna
amplifi
e
coli
strain
purifi
plasmidpurif
kit
qiagen
usa
dissolv
endotoxinfre
pb
final
concentr
gl
store
c
ratio
rang
endotoxin
content
purifi
plasmid
dna
euml
level
effect
immun
respons
underlin
sequenc
restrict
site
human
embryon
kidney
cell
line
atcc
crl
maintain
dulbecco
modifi
eagl
medium
dmem
gibco
brl
supplement
penicillinstreptomycinneomycin
fetal
bovin
serum
fb
cell
incub
c
co
cell
densiti
confluent
transfect
perform
use
transfect
kit
tran
reagent
myru
experiment
group
treat
plasmid
neg
control
treat
plasmid
fortyeight
hour
transfect
cell
harvest
lyse
use
tripledeterg
lysi
buffer
express
protein
cell
separ
sd
polyacrylamid
gel
transfer
nitrocellulos
membran
schleicher
schuell
gmbh
dassel
germani
nitrocellulos
membran
incub
h
tnt
mmoll
trisbas
mmoll
nacl
vv
contain
wv
powder
skim
milk
membran
probe
mous
antisar
nucleoprotein
zyme
laboratori
dilut
tpb
h
wash
four
time
tpb
incub
peroxidas
rabbit
antimous
cappel
dilut
tpb
contain
nonfat
milk
membran
wash
four
time
tpb
develop
use
hyperfilmenhanc
chemiluminesc
amersham
piscataway
nj
eightweekold
femal
balbc
mice
weigh
g
free
adventiti
rodent
pathogen
ectoparasit
endoparasit
use
studi
mice
maintain
certifi
anim
hous
supervis
standard
condit
c
temperatur
rel
humid
photoperiod
h
lightdark
water
dri
pellet
diet
given
ad
libitum
mice
acclimat
day
prior
start
experi
procedur
perform
accord
guidelin
care
use
laboratori
anim
approv
seoul
nation
univers
approv
number
four
group
n
mice
use
studi
group
neg
control
group
sham
control
group
experiment
group
immun
l
pb
group
g
group
g
pvax
group
g
pvax
immun
carri
three
time
interv
intramuscularli
im
electropor
right
quadricep
muscl
inject
electropor
treatment
made
light
anesthesia
induc
mixtur
ketamin
mgkg
xylazin
mgkg
tibiali
anterior
muscl
pair
electrod
needl
mm
probe
insert
muscl
cover
dna
inject
site
electr
puls
deliv
use
electr
puls
gener
electro
squar
porat
ecm
btx
san
diego
usa
four
puls
v
deliv
inject
site
rate
one
puls
per
second
puls
last
ms
follow
four
puls
opposit
polar
describ
previous
serum
antibodi
protein
assess
enzymelink
immunosorb
assay
elisa
mous
sera
collect
day
day
day
final
immun
specif
antibodi
detect
nspecif
immunoglobulin
igg
subclass
assess
elisa
case
recombin
n
ng
protein
express
e
coli
purifi
use
detect
antigen
hrpconjug
goat
antimous
igg
sigma
use
secondari
antibodi
optic
densiti
od
read
nm
use
plate
reader
biorad
usa
valu
obtain
mous
sera
experiment
group
consid
posit
time
control
group
valu
includ
antigenspecif
tcell
prolifer
assay
lpa
perform
describ
brief
day
follow
final
inject
mice
sacrif
singlecel
suspens
prepar
spleen
group
splenocyt
well
medium
sigma
supplement
fb
seed
plate
triplic
cultur
stimul
follow
variou
condit
h
c
co
gml
concanavalin
posit
control
gml
purifi
n
antigen
specif
antigen
gml
bovin
serum
albumin
irrelev
antigen
medium
alon
neg
control
celltit
aqueou
one
solut
reagent
l
promega
usa
ad
well
accord
manufactur
protocol
follow
h
incub
c
absorb
read
nm
prolif
activ
estim
use
stimul
index
si
calcul
mean
antigencontain
well
divid
mean
well
without
antigen
spleen
mice
excis
ground
copper
net
one
hundr
l
suspens
contain
spleen
cell
ad
ml
pb
centrifug
g
min
wash
twice
pb
cell
resuspend
make
cell
suspens
twenti
microlit
antimous
monoclon
antibodi
mab
label
fitc
mab
label
pe
ad
suspens
cell
wash
twice
incub
c
min
final
ml
fluoresc
conserv
solut
ad
cell
detect
fac
calib
flow
cytomet
data
analyz
use
winmdi
softwar
beckton
dickinson
statist
analysi
perform
use
duncan
multipl
rang
test
sa
v
sa
institut
pvalu
consid
statist
signific
fulllength
truncat
fragment
n
gene
clone
express
e
coli
origami
tm
b
plyss
use
express
plasmid
describ
fig
tabl
insert
plasmid
sequenc
prove
correct
induct
iptg
petn
e
coli
hexahistidin
tag
overexpress
expect
size
kda
respect
success
purifi
resin
base
affin
chromatographi
fig
truncat
recombin
protein
identifi
western
blot
mous
sar
n
protein
antibodi
fig
confirm
use
convalesc
sar
patient
sera
posit
healthi
human
sera
neg
antibodi
fig
increas
potenc
specif
immun
respons
fulllength
n
truncat
gene
ligat
contain
cmv
promot
bgh
polyadenyl
sequenc
insert
plasmid
indic
sequenc
prove
correct
fig
order
character
express
sarscov
n
protein
cell
transfect
variou
dna
construct
perform
western
blot
analysi
use
cell
lysat
deriv
dnatransfect
cell
mous
antisar
nucleoprotein
use
western
blot
analysi
shown
fig
lysat
cell
transfect
dna
reveal
protein
band
size
approxim
kda
respect
contrast
protein
detect
lysat
cell
transfect
dna
data
indic
n
dnatransfect
cell
exhibit
level
n
protein
express
compar
plasmid
dna
inserttransfect
cell
control
evalu
humor
immun
respons
dna
vaccin
encod
sarscov
n
protein
perform
elisa
analysi
use
bacteriumderiv
n
protein
sera
mice
ten
day
final
vaccin
two
dna
vaccin
shown
fig
two
group
vaccin
mice
develop
substanti
antibodi
respons
wherea
anim
control
group
pb
show
detect
nspecif
igg
subtyp
profil
antibodi
respons
shown
fig
antisarscov
igg
induc
immun
regimen
igg
antibodi
level
group
show
higher
degre
increas
compar
vaccin
group
although
antibodi
profil
less
similar
group
activ
prolifer
lymphocyt
play
critic
role
humor
cellular
immun
respons
induc
vaccin
therefor
next
evalu
whether
vaccin
electropor
subsequ
immun
could
influenc
antigenspecif
tcell
prolifer
shown
fig
higher
level
lymphocyt
stimul
n
protein
observ
mice
immun
compar
control
pb
p
cell
prolifer
anim
immun
appreci
higher
immun
anim
p
sinc
activ
lymphocyt
among
crucial
compon
antivir
effector
assess
vaccin
mice
fig
flow
cytometr
analysi
unstimul
cell
use
standard
background
respons
littl
variat
nonimmun
mice
compar
control
group
p
cell
increas
ratio
decreas
experiment
group
indic
cytotox
lymphocyt
ctl
activ
induc
recombin
plasmid
ratio
group
higher
group
differ
statist
signific
p
sar
epidem
current
control
howev
absenc
effect
therapeut
agent
rel
new
lethal
viru
anim
origin
compound
threat
potenti
reemerg
call
develop
sar
vaccin
extens
effort
made
fig
nspecif
lymphocyt
prolifer
assay
pool
splenocyt
obtain
mice
five
mice
per
group
immun
dna
vaccin
day
postimmun
splenocyt
stimul
vitro
n
protein
group
con
posit
control
bsa
irrelev
antigen
control
splenocyt
control
group
pb
stimul
n
protein
serv
neg
control
sham
control
stimul
index
si
calcul
use
follow
formula
si
mean
od
con
antigenstimul
prolifer
mean
od
nonstimul
prolifer
bar
repres
mean
si
sd
five
mice
p
p
result
studi
tan
et
al
suggest
earli
day
onset
ill
igm
iga
antin
antibodi
present
blood
day
iga
level
n
protein
high
find
n
protein
induc
strong
iga
respons
parallel
find
tripp
et
al
monoclon
antibodi
n
protein
present
mucos
epithelia
detect
immunohistochemistri
autopsi
sampl
locat
includ
alveolar
epithelium
tracheabronchu
esophagu
gastric
pariet
cell
intestin
tract
strong
immunoreact
toward
n
protein
suggest
protein
may
releas
viru
infect
cell
circul
infect
altern
may
present
antigen
present
cell
apc
cytolysi
target
cell
n
protein
appear
undergo
rapid
mutat
like
protein
coupl
fact
protein
difficult
express
n
protein
could
better
target
develop
serolog
assay
similar
studi
protein
put
antigen
sequenc
also
identifi
n
protein
use
cdna
fulllength
n
protein
express
e
coli
fragment
probe
sar
patient
sera
studi
chen
et
al
four
region
possibl
epitop
identifi
amino
acid
describ
linear
epitop
form
conform
epitop
react
sera
structur
requir
appear
import
antigen
n
protein
keep
mind
protein
microarray
data
express
recombin
n
amino
acid
protein
e
coli
prepar
n
proteinspecif
monoclon
polyclon
antibodi
develop
tool
sar
diagnosi
two
kind
antibodi
antifulllength
n
protein
antiparti
n
protein
obtain
shown
sensit
specif
sarscov
antibodi
test
sarscov
posit
human
sera
compar
human
sera
elisa
system
also
check
polyclon
monoclon
antibodi
crossreact
group
corona
viru
human
corona
porcin
epidem
diarrhea
group
ii
human
corona
mous
hepat
viru
author
unpublish
data
identif
antigen
n
protein
fragment
offer
potenti
target
site
design
epitopebas
vaccin
sar
report
detect
sarscov
proteinspecif
immun
respons
induc
dna
vaccin
respect
found
significantli
high
titr
specif
antibodi
specif
cell
mediat
immun
compar
control
result
indic
n
protein
natur
exist
viru
particl
bind
viral
rna
abl
induc
strong
humor
cellular
immun
respons
induc
dna
vaccin
might
prospect
candid
gene
develop
sarscov
vaccin
shown
dna
vaccin
success
elicit
sarscov
nspecif
humor
tcell
respons
vaccin
mice
also
evid
vaccin
effect
got
result
elisa
system
specif
sensit
higher
author
unpublish
data
data
show
middl
ctermin
region
sarscov
n
protein
antigen
ntermin
region
reflect
publish
report
result
suggest
truncat
recombin
protein
except
ntermin
sar
n
protein
contain
highli
conserv
motif
use
design
dna
vaccin
nucleocapsid
corona
viru
group
contain
tcell
depend
independ
epitop
nude
athym
mice
immun
hbvnucleocapsid
alon
develop
high
titer
igm
antibodi
predomin
antibodi
respons
evid
specif
structur
fold
viral
nucleocapsid
respons
high
immunogen
two
studi
analyz
humor
cellmedi
immun
respons
mice
immun
dna
vaccin
express
nucleocapsid
kim
et
al
show
linkag
nucleocapsid
protein
calreticulin
increas
humor
cellular
immun
respons
vaccin
mice
compar
mice
receiv
dnanucleocapsid
alon
shi
et
al
show
express
membran
protein
augment
specif
respons
induc
sarscov
nucleocapsid
dna
immun
zhu
et
al
show
high
level
antibodi
titer
mice
three
inject
dnanucleocapsid
success
immun
depend
sever
factor
type
antigen
rout
administr
usag
adjuv
widera
et
al
increas
dna
vaccin
deliveri
immunogen
electropor
vivo
studi
mice
immun
electropor
dna
immun
well
model
mice
evalu
best
possibl
paramet
immun
also
type
immun
respons
produc
evid
data
till
date
dna
vaccin
also
seem
promis
human
applic
howev
effect
mice
may
often
vivid
human
henc
certain
safeti
issu
need
taken
care
regard
immunogen
dna
vaccin
human
dna
vaccin
larger
anim
still
total
effect
due
signific
restrict
recent
technolog
mani
characterist
still
remain
consid
prior
develop
dna
vaccin
sarscov
human
present
report
illustr
present
sar
n
dna
vaccin
express
plasmid
induc
specif
immun
respons
mous
howev
run
test
check
protect
effect
challeng
sarscov
next
target
would
evalu
establish
efficaci
sar
dna
vaccin
nonhuman
primat
model
